AW
CCCC icon

Avion Wealth’s C4 Therapeutics CCCC Stock Holding History

Avion Wealth’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-331
Closed -$1K – 1218
2025
Q1 		$1K Hold
331
– – ﹤0.01% 822
2024
Q4 		$1K Hold
331
– – ﹤0.01% 819
2024
Q3 		$1K Hold
331
– – ﹤0.01% 771
2024
Q2 		$1K Hold
331
– – ﹤0.01% 695
2024
Q1 		$3K Hold
331
– – ﹤0.01% 538
2023
Q4 		$2K Buy
+331
New +$755 ﹤0.01% 537

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Avion Wealth's CCCC Position: Q2 2025 in Review

Avion Wealth sold out of C4 Therapeutics (CCCC) in Q2 2025, closing a stake of 331 shares — an estimated $1K sold.

Avion Wealth first reported a position in CCCC in Q4 2023 and held it in 6 quarters. The position peaked at $3K in Q1 2024. 102 funds tracked by Wall St. Rank hold CCCC as of Q2 2025.

  • Avion Wealth reported no remaining C4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Avion Wealth sold 331 C4 Therapeutics shares in Q2 2025, an estimated $1K.
  • Avion Wealth first reported a position in C4 Therapeutics in Q4 2023 and held it in 6 quarters.
  • Avion Wealth's C4 Therapeutics position peaked at $3K in Q1 2024.
  • 102 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2025.

Based on Avion Wealth's 13F filing for Q2 2025, filed 25 Jul 2025.